Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer
- 28 August 2013
- journal article
- clinical trial
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 141 (1) , 119-123
Abstract
The role of aromatase inhibitors combined with gonadotropin-releasing hormone analog in metastatic male breast cancer patients remains unknown. In this retrospective study we evaluated the activity of letrozole combined with a gonadotropin-releasing hormone analog as a first- or second-line therapy for metastatic male breast cancer patients. 19 men entered the study. We did not observe any grade 3 or 4 adverse events. 2 patients (10.5 %) had complete response, 7 patients (36.8 %) experienced a partial response, 7 patients (36.8 %) had stable disease lasting ≥6 months, and 3 patients (15.8 %) had progressive disease. Overall, the disease control rate was 84.2 %. Median progression-free survival was 12.5 months (95 % CI 8.2–16.9), median overall survival was 35.8 months (95 % CI 24.4–49.2), 1- and 2-year survival rates were 89.5 and 67 %, respectively. Interestingly, 3 out of 4 patients treated with the combination following disease progression while on aromatase inhibitor monotherapy confirmed or improved the best overall response observed in the first-line setting. The combination of letrozole and gonadotropin-releasing hormone analog is effective and safe in hormone-receptor positive, metastatic male breast cancer patients.Keywords
This publication has 23 references indexed in Scilit:
- An update on male breast cancer and future directions for research and treatmentEuropean Journal of Pharmacology, 2013
- A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal womenCancer Treatment Reviews, 2013
- Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorshipAnnals of Oncology, 2013
- Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patientsBreast Cancer Research and Treatment, 2012
- Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies N-acetyltransferase-1 (NAT1) as a novel prognostic biomarkerBreast Cancer Research, 2012
- Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancerBreast Cancer Research and Treatment, 2010
- Male Breast Cancer: A Population-Based Comparison With Female Breast CancerJournal of Clinical Oncology, 2010
- Comparative Assessment in Young and Elderly Men of the Gonadotropin Response to Aromatase InhibitionThe Journal of Clinical Endocrinology & Metabolism, 2005
- Estradiol in elderly menThe Aging Male, 2002
- Plasma Precursors of Estrogen. II. Correlation of the Extent of Conversion of Plasma Androstenedione to Estrone with Age1The Journal of Clinical Endocrinology & Metabolism, 1974